Enhanced serum concentrations of Ara‐C using suppositories containing tetrahydrouridine as a deamination inhibitor of Ara‐C

Abstract

Rectal bioavailability of Ara‐C (serum AUC 4 h: 65 μg h−1 ml−1) administered in a suppository formulation containing tetrahydrouridine (a deamination inhibitor) and sodium salicylate (an adjuvant) to dogs was better than that from a suppository formulation without tetrahydrouridine (serum AUC 4 h: 18 μg h−1 ml−1). Copyright © 1986, Wiley Blackwell. All rights reserved